Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

NCT01814800 is registered in ClinicalTrials.gov with ADMA Biologics, Inc. as lead sponsor.

NCT NCT01814800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01814800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
Lead sponsor
ADMA Biologics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2014
Completion date
January 31, 2015
Enrollment
59 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune deficiency disorder